|
|
 |
|
The Leadership Behind Trimeris
Martin A. Mattingly, Chief Executive Officer and member of the Company's board of directors. Dr.
Mattingly was most recently employed at Ambrx, Inc. where he served as President and Chief Executive Officer from 2005 to 2007. Prior to that, Dr. Mattingly served as Executive Vice President and Chief Operating Officer at CancerVax from 2003 to 2005. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. ("Agouron") and Pfizer, Inc. ("Pfizer"). These assignments included General Manager of the Agouron HIV division; Vice President, Product Development Group at Pfizer; and Vice President, Global Marketing Planning at Pfizer. From 1983 to 1996, Dr. Mattingly held various positions in oncology marketing and sales management at Eli Lilly and Company.
Dr. Mattingly holds a Doctor of Pharmacy degree from the University of Kentucky.
Andrew L. Graham, CPA, Corporate Secretary and Chief Financial Officer. Mr. Graham joined Trimeris in September 2004. Prior to joining Trimeris, Mr. Graham served as Chief Accounting Officer at Icoria, Inc. (formerly Paradigm Genetics, Inc.) from 2002 through 2004. At Icoria, Mr. Graham first served as Comptroller and later as Director of Finance from 1999 through 2002. Mr. Graham received his BA and MA degrees in accounting from North Carolina State University, and his MBA from the University of North Carolina at Chapel Hill.
Michael A. Alrutz, General Counsel. Dr. Alrutz previously served as Legal Counsel at Trimeris beginning in 2002. Dr. Alrutz received his B.A. degree in Biology from the University of Pennsylvania and his J.D. from Duke University School of Law. Dr. Alrutz also holds a Ph.D. in Molecular Biology from the Sackler School of Graduate Biomedical Sciences at Tufts University.
Trimeris Board of Directors
Felix J. Baker, PhD has served as a director of Trimeris since April 2004. Dr. Baker is a Managing Member of Baker Bros. Advisors, LLC, which he and his brother, Julian Baker, founded in 2000. Dr. Baker’s firm manages Baker Brothers Investments, a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies. Dr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. He is also a director of Neurogen Corporation, ConjuChem Inc., and Seattle Genetics, Inc. Dr. Baker holds a BS and a PhD in Immunology from Stanford University, where he also completed two years of medical school.
Julian C. Baker has served as a director of Trimeris since April 2004. Mr. Baker is a Managing Member of Baker Bros. Advisors, LLC, which he and his brother, Felix Baker, PhD, founded in 2000. Mr. Baker’s firm manages Baker Brothers Investments, a family of long-term investment funds for university endowments and foundations, which are focused on publicly traded life sciences companies. Mr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. He is also a director of Incyte Corporation, Neurogen Corporation, and Genomic Health, Inc. Mr. Baker holds an AB magna cum laude from Harvard University.
Stephen R. Davis was appointed to the company’s Board of Directors on June 27, 2007. Mr. Davis has been Executive Vice President of Neurogen Corporation since September 2001 and Chief Operating Officer since April 2005. Mr. Davis is also a Director of Neurogen. Mr. Davis joined Neurogen in 1994 as Vice President of Finance and Chief Financial Officer. From 1990 through June 1994, Mr. Davis was employed by Milbank, Tweed, Hadley & McCloy LLP as a corporate and securities attorney. Previously, Mr. Davis practiced as a Certified Public Accountant with Arthur Andersen & Co. Mr. Davis received his BS in accounting from Southern Nazarene University and a JD degree from Vanderbilt University.
James R. Thomas has been a director of the Company
since August 2009. Mr. Thomas is currently a partner of Tatum, LLC in the firm's Life Science and Healthcare division which he joined during 2009. From 1990 to 2009, Mr. Thomas served in various financial positions at Pfizer, Inc. From 2007 to 2009, Mr. Thomas served as CFO of Pfizer's Specialty Markets and Special Entities division. In addition, from 2003 to 2007, Mr. Thomas served as CFO of Greenstone, LLC (Pfizer Generics). Mr. Thomas holds B.S. and M.B.A. degrees from Indiana State University School of Business.
Barry Quart, PharmD was appointed to the company’s Board of Directors on June 27, 2007. Since late 2006, Dr. Quart has served as President and CEO of Ardea Biosciences, Inc., a publicly traded biotechnology firm. From 2002 until December 2006, Dr. Quart was President of Napo Pharmaceuticals, Inc. Prior to Napo, Dr. Quart was Senior Vice President, Pfizer Global Research and Development and the Director of Pfizer’s La Jolla Laboratories. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, since 1999. Prior to joining Agouron in 1993, Dr. Quart spent over ten years at Bristol-Myers Squibb in both Clinical Research and Regulatory Affairs. Dr. Quart has a PharmD from the University of California, San Francisco.
Arthur B. Cohen was appointed to the company’s Board of Directors on February 8, 2008.. Mr. Cohen, is a founder of, and Portfolio Manager at, HealthCor. Prior to establishing HealthCor in September 2005, Mr. Cohen acted as a Portfolio Manager for SAC Capital from January 2000 until March 2005. From 1995 until 2000, Mr. Cohen was responsible for healthcare investments as a Managing Director at Tiger Management, and from 1993 to 1995, he was employed as an Investment Officer at J&W Seligman. Mr. Cohen was also employed as a Vice President at the Bank of New York from 1991 until 1993 and was an Assistant Portfolio Manager of the M.S.B. Fund from 1987 to 1991. Mr. Cohen is a Chartered Financial Analyst. Mr. Cohen graduated from the University of Virginia in 1983 with a B.A. degree in Commerce and received his M.B.A. in Banking and Finance from Hofstra University in 1986.
Joseph P. Healey was appointed to the company’s Board of Directors on February 8, 2008.. Mr. Healey is a founder of, and Portfolio Manager at, HealthCor. Prior to establishing HealthCor in September 2005, Mr. Healey acted as a Portfolio Manager for SAC Capital from January 2000 until March 2005. Prior to joining SAC Capital, Mr. Healey was a healthcare Portfolio Manager at Kingdon Capital Management from 1997 to 2000 and was employed as an Analyst and Portfolio Manager at the Dreyfus Corporation from 1992 until 1997. Mr. Healey also served as a First Lieutenant in the United States Army Medical Service Corp at the Walter Reed Army Medical Center from 1988 to 1992. Mr. Healey is a Chartered Financial Analyst. Mr. Healey graduated from Boston University in 1988 with a B.A. in Biomedical
|
|
|
|
 |
| To transform science into medicine is like turning hope into triumph. |
|
 |
|
|
|